JMP reiterates Myriad at market outperform

Myriad Genetics Inc. was reiterated by JMP Securities analyst Charles C. Duncan at a market outperform rating with $25 price target after follow-on data from the company's phase 2 Flurizan study showed improvement in Alzheimer's disease progression. The data points to a gain in cognitive function in mild Alzheimer's patients and supports continued evaluation in ongoing phase 3 study. Shares of the Salt Lake City molecular and diagnostic-product development company were down 33 cents, or 1.75%, at $18.48 on volume of 288,453 shares versus the three-month running average of 402,635 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.